



Appendix 1. Respondents' answer to each question of the EQ-5D questionnaire for standard dosing arm (A) and pharmacogenomics-guided dosing arm (B). The EQ-5D questionnaire contains 5 questions. Each question measures a dimension of health in 3 levels of severity. In Figure 1, questions 1-5 refer to mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. Choices A, B and C represent no, moderate, or extreme problems in each dimension. Figure 1 demonstrates that pharmacogenomics-guided dosing has a higher beneficial effect on anxiety or depression (question 5) as the number of patients that do not feel anxious/depressed increases by 22.85% after taking genotyping tests. In comparison, pharmacogenomics-guided dosing does not have a considerable effect on other dimensions of patients' quality of life.



Appendix 2. Bar chart of sensitivity analysis for utility.



Appendix 3. Bar chart of sensitivity analysis for genotyping test cost.